Loading...

BioLineRx

Nasdaq:BLRX
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BLRX
Nasdaq
₪197M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
  • BioLineRx has significant price volatility in the past 3 months.
BLRX Share Price and Events
7 Day Returns
1.7%
NasdaqCM:BLRX
0.3%
US Biotechs
-1.4%
US Market
1 Year Returns
-59.8%
NasdaqCM:BLRX
-4.8%
US Biotechs
1.6%
US Market
BLRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioLineRx (BLRX) 1.7% 0.2% -10.7% -59.8% -62.3% -81.8%
US Biotechs 0.3% -2.6% -6% -4.8% 3.6% 11%
US Market -1.4% -3.9% 0.1% 1.6% 33.2% 38.2%
1 Year Return vs Industry and Market
  • BLRX underperformed the Biotechs industry which returned -4.8% over the past year.
  • BLRX underperformed the Market in United States of America which returned 1.6% over the past year.
Price Volatility
BLRX
Industry
5yr Volatility vs Market
Related Companies

Value

 Is BioLineRx undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioLineRx. This is due to cash flow or dividend data being unavailable. The share price is $0.366.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioLineRx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioLineRx's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:BLRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.20
TASE:BLRX Share Price ** TASE (2019-05-24) in ILS ₪1.35
TASE:BLRX Share Price converted to USD reporting currency Exchange rate (ILS/ USD) 0.277 $0.38
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 18.23x
United States of America Market PE Ratio Median Figure of 3,086 Publicly-Listed Companies 17.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioLineRx.

NasdaqCM:BLRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TASE:BLRX Share Price ÷ EPS (both in USD)

= 0.38 ÷ -0.20

-1.89x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioLineRx is loss making, we can't compare its value to the US Biotechs industry average.
  • BioLineRx is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does BioLineRx's expected growth come at a high price?
Raw Data
NasdaqCM:BLRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.89x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
64.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.14x
United States of America Market PEG Ratio Median Figure of 2,121 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioLineRx, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioLineRx's assets?
Raw Data
NasdaqCM:BLRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.35
TASE:BLRX Share Price * TASE (2019-05-24) in ILS ₪1.35
TASE:BLRX Share Price converted to USD reporting currency Exchange rate (ILS/ USD) 0.277 $0.38
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.16x
United States of America Market PB Ratio Median Figure of 5,208 Publicly-Listed Companies 1.8x
NasdaqCM:BLRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TASE:BLRX Share Price ÷ Book Value per Share (both in USD)

= 0.38 ÷ 0.35

1.09x

* Primary Listing of BioLineRx.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioLineRx is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess BioLineRx's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioLineRx has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioLineRx expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
64.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioLineRx expected to grow at an attractive rate?
  • BioLineRx's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • BioLineRx's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare BioLineRx's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:BLRX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:BLRX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 64.9%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:BLRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:BLRX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 82 55 2
2022-12-31 44 18 2
2021-12-31 12 -14 2
2020-12-31 1 -26 2
2019-12-31 0 -24 2
NasdaqCM:BLRX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -22 -23
2018-12-31 -24 -23
2018-09-30 -25 -25
2018-06-30 -26 -26
2018-03-31 -24 -26
2017-12-31 -21 -24
2017-09-30 -18 -21
2017-06-30 -15 -18
2017-03-31 -14 -17
2016-12-31 -15 -16
2016-09-30 -14 -15
2016-06-30 -14 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioLineRx's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if BioLineRx is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:BLRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from BioLineRx Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BLRX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
NasdaqCM:BLRX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.20
2018-12-31 -0.21
2018-09-30 -0.23
2018-06-30 -0.24
2018-03-31 -0.25
2017-12-31 -0.27
2017-09-30 -0.27
2017-06-30 -0.28
2017-03-31 -0.30
2016-12-31 -0.28
2016-09-30 -0.27
2016-06-30 -0.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioLineRx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioLineRx's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioLineRx has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioLineRx performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioLineRx's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioLineRx does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioLineRx's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioLineRx's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BioLineRx's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioLineRx Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BLRX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -22.92 5.42 19.13
2018-12-31 -22.96 5.80 19.81
2018-09-30 -24.67 5.47 20.79
2018-06-30 -25.59 5.69 21.41
2018-03-31 -25.70 5.58 20.99
2017-12-31 -24.35 5.73 19.51
2017-09-30 -21.28 5.69 16.25
2017-06-30 -18.37 5.82 13.55
2017-03-31 -17.21 5.81 12.23
2016-12-31 -15.84 5.34 11.18
2016-09-30 -15.21 5.19 11.04
2016-06-30 -12.50 4.68 10.67
2016-03-31 -13.58 4.83 10.82
2015-12-31 -14.40 4.71 11.49
2015-09-30 -14.94 5.24 11.96
2015-06-30 -14.02 5.30 12.36
2015-03-31 -13.27 5.15 12.26
2014-12-31 -11.08 5.39 11.77
2014-09-30 -11.05 4.92 9.63
2014-06-30 -15.81 4.92 9.13
2014-03-31 -16.04 5.09 11.45
2013-12-31 -17.02 4.80 12.17
2013-09-30 -19.99 5.01 18.00
2013-06-30 -20.75 4.96 19.57
2013-03-31 -19.52 4.73 20.59
2012-12-31 -20.43 4.62 17.22
2012-09-30 -16.85 4.08 15.06
2012-06-30 -13.15 4.06 14.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioLineRx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioLineRx has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioLineRx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioLineRx's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioLineRx has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioLineRx's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioLineRx's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioLineRx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioLineRx's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioLineRx's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioLineRx Company Filings, last reported 1 month ago.

NasdaqCM:BLRX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 45.89 10.69 40.61
2018-12-31 41.32 8.73 30.15
2018-09-30 40.59 0.18 35.00
2018-06-30 46.19 0.20 41.13
2018-03-31 49.02 0.23 44.20
2017-12-31 52.88 0.25 49.48
2017-09-30 59.03 0.27 55.01
2017-06-30 57.43 0.30 52.56
2017-03-31 35.72 0.32 30.37
2016-12-31 35.03 0.34 35.62
2016-09-30 38.61 0.37 38.91
2016-06-30 42.56 0.39 41.82
2016-03-31 46.00 0.41 45.01
2015-12-31 47.61 0.44 47.66
2015-09-30 50.67 0.46 50.71
2015-06-30 51.82 0.00 54.79
2015-03-31 54.19 0.00 57.49
2014-12-31 31.81 0.00 34.68
2014-09-30 26.88 0.00 29.68
2014-06-30 29.31 0.00 33.23
2014-03-31 32.34 0.00 37.46
2013-12-31 11.72 0.00 18.22
2013-09-30 14.24 0.00 20.32
2013-06-30 17.35 0.00 22.96
2013-03-31 20.30 0.01 28.10
2012-12-31 14.98 0.04 21.37
2012-09-30 18.35 0.04 25.80
2012-06-30 24.01 0.07 30.69
  • BioLineRx's level of debt (23.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 23.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioLineRx has sufficient cash runway for 1.3 years based on current free cash flow.
  • BioLineRx has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 27.9% each year.
X
Financial health checks
We assess BioLineRx's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioLineRx has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioLineRx's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioLineRx dividends.
If you bought $2,000 of BioLineRx shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioLineRx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioLineRx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:BLRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2007 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:BLRX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioLineRx has not reported any payouts.
  • Unable to verify if BioLineRx's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioLineRx's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioLineRx has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioLineRx's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioLineRx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioLineRx has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioLineRx's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Phil Serlin
COMPENSATION $846,000
AGE 58
TENURE AS CEO 2.6 years
CEO Bio

Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLineRx, Ltd. from May 24, 2009 to October 10, 2016 and also served as its Principal Accounting Officer until October 10, 2016. Mr. Serlin served as the Chief Financial Officer and Chief Operating Officer of Kayote Networks, Inc from January 2008 to August 2008. He served as Vice President of Finance at TesCom Software Systems Testing Ltd. from January 2006 to December 31, 2007 and served as its Chief Financial Officer from January 2006 to December 2007. Mr. Serlin joined Tescom from Chiaro Networks Ltd., where he served as Corporate Controller and Finance Manager since 2000 and also served as its Vice President of Finance. From January 2000 to December 2005, he served as Chief Accounting Officer for Chiaro Networks Ltd. He has over 25 years of experience in accounting and finance. He has extensive experience of financial reporting and regulatory affairs. From June 1986 to December 1992, he served as senior accountant/analyst and Technical Accounting Advisor/Investigator at the US Securities and Exchange Commission. He served in a number of senior managerial roles at leading Israeli companies. From January 1994 to December 1999, he served as Senior Manager at Deloitte Touche Tohmatsu (Brightman, Almagor & Co), where he headed the SEC and U.S. accounting department at the Tel Aviv national office. He served senior financial positions with other publicly traded companies, as well as at Deloitte and the Securities and Exchange Commission (SEC). He served as an Independent Director of Vascular Biogenics Ltd. since February 11, 2015 until June 7, 2018. He served as a Director of Vringo, Inc. from May 2010 to July 19, 2012. He served as Director of Kitov Pharmaceuticals Holdings Ltd. since July 2013 until March 2016. He is a Certified Public Accountant. Mr. Serlin is a Member of the American Institute of Certified Public Accountants and holds a Master of Business Administration from the George Washington University, USA. He holds a Master's degree in Economics and Public Policy from The George Washington University. Mr. Serlin holds a BS Degree in Accounting from Yeshiva University.

CEO Compensation
  • Phil's compensation has increased whilst company is loss making.
  • Phil's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BioLineRx management team in years:

2.6
Average Tenure
51.5
Average Age
  • The tenure for the BioLineRx management team is about average.
Management Team

Phil Serlin

TITLE
Chief Executive Officer
COMPENSATION
$846K
AGE
58
TENURE
2.6 yrs

Mali Zeevi

TITLE
Chief Financial Officer
COMPENSATION
$450K
AGE
42
TENURE
2.6 yrs

Ella Sorani

TITLE
Vice President Research & Development
COMPENSATION
$445K
AGE
50
TENURE
2.3 yrs

Abi Vainstein-Haras

TITLE
Vice President of Clinical Development
COMPENSATION
$495K
AGE
43
TENURE
2.3 yrs

Norman Kotler

TITLE
Internal Enforcement Officer
AGE
66

Razi Fried

TITLE
Budget Control Manager and Treasurer

Leah Klapper

TITLE
Consultant
COMPENSATION
$343K
AGE
53
TENURE
3.4 yrs
Board of Directors Tenure

Average tenure and age of the BioLineRx board of directors in years:

8.7
Average Tenure
70
Average Age
  • The tenure for the BioLineRx board of directors is about average.
Board of Directors

Aharon Schwartz

TITLE
Chairman of the Board
AGE
75
TENURE
15.3 yrs

Nurit Benjamini

TITLE
External Director
COMPENSATION
$96K
AGE
51
TENURE
8.8 yrs

Michael Anghel

TITLE
Director
COMPENSATION
$26K
AGE
79
TENURE
8.7 yrs

Rafi Hofstein

TITLE
Director
COMPENSATION
$499K
AGE
69
TENURE
16.3 yrs

J. Ciechanover

TITLE
Member of Oncology Scientific Advisory Board
AGE
71

Yosef Yarden

TITLE
Member of Oncology Scientific Advisory Board
TENURE
3.4 yrs

Avi Molcho

TITLE
External Director
COMPENSATION
$94K
AGE
60
TENURE
8.8 yrs

Barbar-Jean Bormann-Kennedy

TITLE
Director
AGE
59
TENURE
5.8 yrs

Sandra Panem

TITLE
Director
AGE
71
TENURE
5.3 yrs

Jorge Cortes

TITLE
Member of Oncology Scientific Advisory Board
TENURE
3.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess BioLineRx's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioLineRx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech’s Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is based in Modi’in, Israel.

Details
Name: BioLineRx Ltd.
BLRX
Exchange: NasdaqCM
Founded: 2003
₪54,594,956
145,461,461
Website: http://www.biolinerx.com
Address: BioLineRx Ltd.
Modi’in Technology Park,
2 HaMa’ayan Street,
Modi’in,
7177871,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TASE BLRX Ordinary Shares The Tel-Aviv Stock Exchange IL ILS 13. Feb 2007
NasdaqCM BLRX SPON ADR EACH REPR 10 ORD Nasdaq Capital Market US USD 25. Jul 2011
DB YP2 SPON ADR EACH REPR 10 ORD Deutsche Boerse AG DE EUR 25. Jul 2011
Number of employees
Current staff
Staff numbers
48
BioLineRx employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/27 00:25
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/14
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.